Antibodies

26 Jan 2009 Access Pharmaceuticals Presents new Combination Data on the Company s Angiolix(R) Therapeutic Monoclonal Antibody
26 Jan 2009 Selexys Pharmaceutical Corporation and Cytovance(R) Biologics Sign Deal for the Process Development and cGMP Manufacture of Selexys Pharmaceutical Corporation’s Product HPL1 Monoclonal Antibody (Mab)
26 Jan 2009 BioInvent and ThromboGenics Receive Technology Transfer Success Fee from Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
22 Jan 2009 XOMA Receives Milestone Payment From Pfizer Under Antibody Technology License
22 Jan 2009 ZEVALIN(R) Produced 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma Study
22 Jan 2009 New Biologic Stelara(R) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
22 Jan 2009 RoACTEMRA approved in Europe to treat patients suffering from Rheumatoid Arthritis
22 Jan 2009 Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
21 Jan 2009 Seattle Genetics Receives Special Protocol Assessment for SGN-35 Pivotal Trial in Hodgkin Lymphoma
20 Jan 2009 Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer
19 Jan 2009 MorphoSys Provides Update on Pipeline Activities in 2009
14 Jan 2009 Ablynx Announces Technical Advances in its Nanobody(R) Platform Technology: Enhanced Benefits from Pulmonary Delivery and Half-Life Extension
14 Jan 2009 Merck KGaA: New Data Reinforce Consistent Efficacy Profile of Erbitux in First-Line mCRC Patients with KRAS Wild-Type Tumors
14 Jan 2009 Cephalon Signs Option Agreement to Acquire Ception Therapeutics
13 Jan 2009 InNexus Biotechnology Completes Preclinical Study Confirming In Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting with FDA
12 Jan 2009 Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
09 Jan 2009 ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
06 Jan 2009 YM Bioscience Receives Clearance to Initiate Randomized Double-Blind Clinical Trials of Nimotuzumab in Lung Cancer and Brain Metastases form Lung Cancer
05 Jan 2009 UCB receives Complete Response Letter from U.S. FDA for use of Cimzia(R) in rheumatoid arthritis patients
05 Jan 2009 Genmab Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck Cancer
05 Jan 2009 Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients
23 Dec 2008 Phase II study shows trifunctional antibody Removab(R) (catumaxomab) well tolerated in treatment of gastric cancer
19 Dec 2008 FDA Issues Complete Response Letter to Centocor fot Ustekinumab Biologis License Application
19 Dec 2008 Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer
18 Dec 2008 Genmab Sells Arzerra Co-Promotion Rights to GlaxoSmithKline

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top